Segregating the Cerebral Mechanisms of Antidepressants and Placebo in Fibromyalgia

被引:17
|
作者
Jensen, Karin B. [1 ,2 ]
Petzke, Frank [3 ]
Carville, Serena [4 ]
Choy, Ernest [5 ]
Fransson, Peter [6 ]
Gracely, Richard H. [7 ]
Vitton, Olivier [8 ]
Marcus, Hanke [9 ]
Williams, Steven C. R. [10 ]
Ingvar, Martin [6 ,11 ]
Kosek, Eva [6 ,11 ]
机构
[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA
[2] Athinoula Martinos Ctr Biomed Imaging, Boston, MA USA
[3] Univ Hosp, Ctr Anesthesiol Emergency & Intens Care Med, Gottingen, Germany
[4] Royal Coll Physicians, Natl Clin Guideline Ctr, London NW1 4LE, England
[5] Cardiff Univ, Sch Med, Cardiff CF10 3AX, S Glam, Wales
[6] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[7] Univ N Carolina, Ctr Neurosensory Disorders, Chapel Hill, NC USA
[8] Pierre Fabre, Boulogne, France
[9] Univ Cologne, Dept Anesthesiol & Postoperat Intens Care Med, Cologne, Germany
[10] Kings Coll London, Inst Psychiat, Ctr Neuroimaging Sci, London WC2R 2LS, England
[11] Karolinska Inst, Osher Ctr Integrat Med, Stockholm, Sweden
来源
JOURNAL OF PAIN | 2014年 / 15卷 / 12期
关键词
Antidepressive agents; fibromyalgia; milnacipran; magnetic resonance imaging; placebos; DEFAULT-MODE NETWORK; DOUBLE-BLIND; PAIN MODULATION; BRAIN; DULOXETINE; OSTEOARTHRITIS; SENSITIVITY; MILNACIPRAN; EFFICACY;
D O I
10.1016/j.jpain.2014.09.011
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Antidepressant drugs are commonly used to treat fibromyalgia, but there is little knowledge about their mechanisms of action. The aim of this study was to compare the cerebral and behavioral response to positive treatment effects of antidepressants or placebo. Ninety-two fibromyalgia patients participated in a 12-week, double-blind, placebo-controlled clinical trial with milnacipran, a serotonin-norepinephrine reuptake inhibitor. Before and after treatment, measures of cerebral pain processing were obtained using functional magnetic resonance imaging. Also, there were stimulus response assessments of pressure pain, measures of weekly pain, and fibromyalgia impact. Following treatment, milnacipran responders exhibited significantly higher activity in the posterior cingulum compared with placebo responders. The mere exposure to milnacipran did not explain our findings because milnacipran responders exhibited increased activity also in comparison to milnacipran nonresponders. Stimulus response assessments revealed specific antihyperalgesic effects in milnacipran responders, which was also correlated with reduced clinical pain and with increased activation of the posterior cingulum. A short history of pain predicted positive treatment response to milnacipran. We report segregated neural mechanisms for positive responses to treatment with milnacipran and placebo, reflected in the posterior cingulum. The increase of pain-evoked activation in the posterior cingulum may reflect a normalization of altered default mode network processing, an alteration implicated in fibromyalgia pathophysiology. Perspective: This study presents neural and psychophysical correlates to positive treatment responses in patients with fibromyalgia, treated with either milnacipran or placebo. The comparison between placebo responders and milnacipran responders may shed light on the specific mechanisms involved in antidepressant treatment of chronic pain. (C) 2014 by the American Pain Society
引用
收藏
页码:1328 / 1337
页数:10
相关论文
共 50 条
  • [1] Resting state connectivity correlates with drug and placebo response in fibromyalgia patients
    Schmidt-Wilcke, T.
    Ichesco, E.
    Hampson, J. P.
    Kairys, A.
    Peltier, S.
    Harte, S.
    Clauw, D. J.
    Harris, R. E.
    NEUROIMAGE-CLINICAL, 2014, 6 : 252 - 261
  • [2] Placebo effect in pharmacological management of fibromyalgia: a meta-analysis
    Migliorini, Filippo
    Maffulli, Nicola
    Eschweiler, Jorg
    Betsch, Marcel
    Tingart, Markus
    Colarossi, Giorgia
    BRITISH MEDICAL BULLETIN, 2021, 139 (01) : 73 - 85
  • [3] Are antidepressants effective in fibromyalgia?
    Thomas, E
    Blotman, F
    JOINT BONE SPINE, 2002, 69 (06) : 531 - 533
  • [4] A Pooled Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials of Milnacipran Monotherapy in the Treatment of Fibromyalgia
    Geisser, Michael E.
    Palmer, Robert H.
    Gendreau, R. Michael
    Wang, Yong
    Clauw, Daniel J.
    PAIN PRACTICE, 2011, 11 (02) : 120 - 131
  • [6] Duloxetine and other antidepressants in the treatment of patients with fibromyalgia
    Arnold, Lesley M.
    PAIN MEDICINE, 2007, 8 : S63 - S74
  • [7] Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis
    Haeuser, W.
    Sarzi-Puttini, P.
    Toelle, T. R.
    Wolfe, F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (06) : S78 - S87
  • [8] The Role of Antidepressants in the Management of Fibromyalgia Syndrome A Systematic Review and Meta-Analysis
    Haeuser, Winfried
    Wolfe, Frederick
    Toelle, Thomas
    Ueceyler, Nurcan
    Sommer, Claudia
    CNS DRUGS, 2012, 26 (04) : 297 - 307
  • [9] Treatment of Fibromyalgia Syndrome With Antidepressants A Meta-analysis
    Haeuser, Winfried
    Bernardy, Kathrin
    Ueceyler, Nurcan
    Sommer, Claudia
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (02): : 198 - 209
  • [10] A combination of pain indices based on momentary assessments can predict placebo response in patients with fibromyalgia syndrome
    Obbarius, Alexander
    Schneider, Stefan
    Stone, Arthur A.
    PAIN, 2021, 162 (02) : 543 - 551